Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India (SPOTLIGHT)

About the study

This is a multicenter, prospective, single-arm observational non-interventional study (NIS), which will be conducted in various countries in the Middle East and India.

Study point of contact

Novartis Pharmaceuticals
+41613241111
[email protected]
Novartis Pharmaceuticals

Locations

1 Bahrain site

1 India site

1 Kuwait site

1 Qatar site

1 Saudi Arabia site

1 United Arab Emirates site

Age

16 Years - 99 Years

Study type

Observational

Gender

All

Interventions

Other

participation requirements

Male and female patients with clinical diagnosis of SCD (based on laboratory parameters) of any genotype.
Patients newly initiated on treatment with locally approved crizanlizumab.
Patients aged 16 years or older at crizanlizumab initiation.

participation restrictions

Patients who did not provide informed consent.
Patients who received a stem cell transplant at time of enrollment.
Patients who participated in or are participating in a clinical trial at time of enrollment or in the 12 months prior to starting commercial crizanlizumab.
According to the investigator’s opinion, the patient is an unlikely candidate to provide an accurate medical history and/or to obtain long-term follow-up information for any reasons such as unavailability or severe concomitant illnesses.

Locations

  • Manama, Bahrain, Novartis Investigative Site
  • Guwahati, India, Novartis Investigative Site
  • Al Ahmadi, Kuwait, Novartis Investigative Site
  • Doha, Qatar, Novartis Investigative Site
  • Jazan, Saudi Arabia, Novartis Investigative Site
  • Al Ain Abu Dhabi, United Arab Emirates, Novartis Investigative Site
Last updated 2022-06-01